Quantcast

Latest Bronchodilator Stories

2014-10-15 12:31:48

The COPD Market Will Fracture with the Continuing Entry of LABA/LAMAs and Other Later-to-Market Bronchodilators, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.

2014-09-08 12:30:18

Additionally, data from the WISDOM trial on stepwise withdrawal of ICS in COPD was also presented at ERS and simultaneously published in the New England Journal of Medicine RIDGEFIELD,

2014-09-04 23:03:46

MedicationDiscountCard.com offers Veramyst discount cards, along with discount cards for other similar medications.

2014-06-19 08:28:42

BURLINGTON, ON, June 19, 2014 /CNW/ - Results from a Phase III 52 week study, show tiotropium (delivered via Respimat(®)*)5µg, a once-daily long-acting anticholinergic bronchodilator, is efficacious

2014-04-30 20:23:46

LONDON, April 30, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse(TM) Ellipta(®) (umeclidinium)

2014-04-24 12:28:48

Each of the Emerging LABA/LAMA Fixed-Dose Combinations Has Advantages Over Current Therapies on Efficacy Measures, According to Findings from Decision Resources Group BURLINGTON, Mass., April

2014-04-23 23:04:20

New research report “COPD Drug Market Opportunity & Clinical Pipeline Analysis” worked out by Kuick Research is now available at MarketPublishers.com.

2014-01-13 16:25:12

-- Ultibro(TM) Breezhaler®1(QVA149), a long-term once-daily dual bronchodilator, received Health Canada approval on December 23rd 2013 for the treatment of


Word of the Day
abactinal
  • Pertaining to the surface or end opposite to the mouth in a radiate animal.
The word 'abactinal' comes from a Greek root meaning 'ray' and a Latin prefix meaning 'away'.
Related